E. K. Yaralieva

E. K. Yaralieva

Auto-generated profile, based on publicly available information

E. K. Yaralieva

National Medical Research Center for Therapy and Preventive Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
ISI. A. Skripnikova
I. A. Skripnikova
EYE. K. Yaralieva
E. K. Yaralieva
RMRoman Myasnikov
Roman Myasnikov
The redistribution of body composition components in heart failure (CHF) is an urgent and poorly understood issue. Despite the significant impact of a decrease in muscle mass, redistribution of fat mass on the course and prognosis of HF, body composition is rarely taken into account in the treatment of this disease. In this regard, the purpose of this review was to systematize the available data and draw the attention of clinicians to this problem. The data presented in the review make it possible to consider the components of body composition as controllable factors, the normalization of which improves the prognosis in patients with HF. The study of pathophysiological mechanisms for the development of body composition anomalies in HF will make it possible to search for new therapeutic targets. Assessment of body composition will make it possible to develop an individual strategy for the treatment of HF, including a set of non-drug measures.

7 July 2022 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ISI. A. Skripnikova
I. A. Skripnikova
EYE. K. Yaralieva
E. K. Yaralieva
ODO. M. Drapkina
O. M. Drapkina
This literature review reflects modern ideas about the combination of heart failure (HF) and osteoporosis, common risk factors for these diseases, and pathophysiological mechanisms of metabolic bone diseases in HF. Despite a growing number of studies on the combined cardiovascular and skeletal system pathology, the relationship between a decrease in bone mineral density and HF risk remains poorly understood. Both conditions are common causes of disability, death, prolonged hospitalizations and a significant reduction in quality of life, while its combination exacerbates their course and increases the incidence of adverse outcomes, which is a heavy burden for a patient and health care in general. Keywords: heart failure, osteoporosis, bone mineral density, bone metabolism.

11 August 2025 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ISI. A. Skripnikova
I. A. Skripnikova
OKO. V. Kosmatova
O. V. Kosmatova
MKM. A. Kolchina
M. A. Kolchina
EYE. K. Yaralieva
E. K. Yaralieva
OIO. Yu. Isaykina
O. Yu. Isaykina
ОИО. Ю. Исайкина
О. Ю. Исайкина
Aim. To study the relationships between vascular wall parameters and bone mineral density (BMD) over a 10-year period.Material and methods. The study included 93 menopausal women without clinical manifestations of atherosclerosis at the baseline stage, who underwent outpatient examination twice with an interval of 10 years. Measurement of pulse wave velocity and augmentation index (AI) using applanation tonometry, carotid ultrasound to determine the intima-­media thickness (IMT) and register plaques, and measurement of BMD using dual-energy X-ray absorptiometry were performed at both visits.Results. Over a 10-year period, an increase in AI, IMT, and plaque count (p<0,001) and a decrease in BMD were noted in the femoral neck and proximal femur (p<0,001), but not in the spine. Multivariate regression analysis adjusted for factors identified at the baseline visit (age, postmenopause duration, body mass index, hypertension, and cardiovascular and osteoporosis therapy) showed that AI, IMT, and plaque presence independently contributed to the decrease in bone mass. Pulse wave velocity and the number of atherosclerotic plaques did not act as independent factors in the decrease in BMD.Conclusion. Over a long period of time, a stable negative association was maintained between AI, IMT, the plaque presence, and bone mass, which did not depend on fracture and cardiovascular risk factors, as well as the use of antiresorptive and cardiovascular therapy.

28 December 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
ISI. A. Skripnikova
I. A. Skripnikova
EYE. K. Yaralieva
E. K. Yaralieva
RMRoman Myasnikov
Roman Myasnikov
OKOlga Kulikova
Olga Kulikova
VNV. E. Novikov
V. E. Novikov
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To assess the body composition and functional activity (FA) parameters in men with heart failure (HF) of various nature depending on the stage, class and echocardiographic characteristics of the disease.Material and methods. The study included 100 men aged 23-70 years. The main group consisted of 60 men with HF, the control group — 40 men without HF. Quantitative body composition assessment (fat, lean and bone body mass) was carried out using dual-energy X-ray absorptiometry (DXA). Physical activity was assessed using handgrip test, short physical performance battery (SPPB) test, 6-minute walk test (6MWT), and Timed Up and Go (TUG) test.Results. In the HF group, there were a significant decrease in total bone mass, trunk and limb bone mass, total muscle mass, trunk and limbs’ muscle mass, appendicular skeletal muscle index (ASMI), and FA as HF class increased. Fat mass did not differ in individuals with different HF class and stage. HF class was an independent factor in the reduction of total bone mass (b=-301,9, p=0,015), total muscle mass (b=-1903, p=0,03), limb bone mass (b=-147,6, p=0,013) and appendicular muscle mass (AMM) (b=-1903, p=0,001). Total bone mass (b=-2,637, p=0,02) and AMM (b=-3,512, p=0,01) were independently associated with the Vasilenko-Strazhesko HF stage. AMM also had an independent association with left ventricular ejection fraction (LVEF) (b=0,274, p=0,03). The average body composition scores did not differ between the study and control groups, while the scores of handgrip test, 6MWT, SPPB and TUG test were significantly worse in the HF group. NYHA HF class, stage of HF, LVEF, left ventricular end-diastolic volume (LVEDV) and pulmonary artery systolic pressure (PASP) made an independent contribution to FA decrease in men with HF.Conclusion. In patients with HF, there was deterioration in musculoskeletal parameters depending on HF class, stage and LVEF, without significant differences compared to the control group. There was no association of fat mass with the disease, clinical and echocardiographic characteristics. The average parameters of muscle strength and tests of FA were reduced in men with HF compared with the control group and depended on the NYHA class and stage of HF, LVEF, LVEDV, and PASP.

3 July 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ISI. A. Skripnikova
I. A. Skripnikova
NAN. A. Alikhanova
N. A. Alikhanova
EYE. K. Yaralieva
E. K. Yaralieva
MMM. A. Myagkova
M. A. Myagkova
VNV. E. Novikov
V. E. Novikov
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To assess the relationship of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels with vascular wall condition and bone mineral density (BMD) in postmenopausal women.Material and methods. The cross-sectional study included 107 outpatients aged 45-82 years who signed informed consent. The inclusion criterion was a menopause during ≥1 year. The level of serum NT-proBNP was determined by electrochemiluminescence. BMD was assessed by dual energy x-ray absorptiometry. Intima-media thickness (IMT), the presence and number of atherosclerotic plaques were evaluated using carotid duplex scanning. Pulse wave velocity (PWV) and augmentation index were estimated by applanation tonometry. To assess 10-year cardiovascular risk, the SCORE high-risk charts were used. Using the Russian model of FRAX® score, 10-year fracture risk was assessed.Results. NT-proBNP level in women with postmenopause >10 years was significantly higher than in those with postmenopause <5 years — 98,7 vs 56,3 pg/ml (p<0,001), but there was no independent relationship according to the regression analysis. According to multivariate regression analysis adjusted for age, menopause duration, systolic blood pressure, hypercholesterolemia, smoking, elevated C-reactive protein and interleukin-6 levels, there were independent relationship between the following parameters: NT-proBNP and IMT (β=2,38, p<0,03), NT-proBNP and PWV (β=1,76, p<0,001). NT-proBNP level in patients with osteoporosis was significantly higher than in women with normal bone mass (p<0,01). A negative correlation was observed between NT-proBNP and BMD of the proximal femur (r=-0,26, p<0,05), while the relationship between BMD of the lumbar vertebrae (L1-L4) and NT-proBNP did not reach significance. In multivariate regression analysis, this relationship has not been confirmed. A positive correlation was obtained between cardiovascular risk (SCORE) and NT-proBNP levels (r=0,28, p<0,001). NT-proBNP levels did not differ in women with a high and low 10-year risk of both major osteoporotic fractures and femoral fractures.Conclusion. An independent relationship of NT-proBNP with vascular stiffness and preclinical atherosclerosis was demonstrated: IMT and PWV. This indicates the participation of NT-proBNP in the atherosclerosis development. The association of elevated NT-proBNP levels with osteoporosis is significant, but not independent, and is apparently related to other factors.

25 October 2025 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
EYE. K. Yaralieva
E. K. Yaralieva
ISI. A. Skripnikova
I. A. Skripnikova
RMRoman Myasnikov
Roman Myasnikov
OKOlga Kulikova
Olga Kulikova
VNV. E. Novikov
V. E. Novikov
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To study the associations of N-terminal pro-brain natriuretic peptide (NT-proBNP) level with body composition parameters in comparison with body mass index (BMI) in men with chronic heart failure (CHF). Material and methods. The study included 60 men aged 20-70 years with CHF of various etiologies and reduced or mildly reduced left ventricular ejection fraction (LVEF). The BMI was calculated using the Quetelet formula: [BMI = body weight (kg)/height (m2)]. Quantitative body composition (fat, muscle, and bone mass) was determined using dual-energy X-ray absorptiometry. NT-proBNP level was determined with method of chemiluminescent enzyme immunoassay using MAGTRATION technology. Results. NT-proBNP level in men with normal body weight was significantly higher than in overweight and obese individuals (680 [427; 2994], 446 [381; 1667], 300 [226; 967] pg/ml (p<0.05), respectively). The amount of both fat and muscle mass was significantly higher in obese individuals, however, in a linear regression analysis adjusted for age NT-proBNP levels were independently associated only with the appendicular muscle mass and the appendicular skeletal muscle index. Conclusion. Patients with CHF and obesity have lower NT-proBNP values than those with normal body weight. An independent inverse association of NT-proBNP level with BMI and with indicators of muscle mass, but not body fat, was demonstrated. These findings suggest that the muscle component of body weight contributes to the lower NT-proBNP values in CHF patients with high BMI.